Sarcoma Reagents | abinScience

Home > Featured Products > Oncology Research > Sarcoma

Sarcomas are a heterogeneous group of mesenchymal malignancies with >70 histological subtypes. Subtype-specific molecular markers — MDM2 amplification (liposarcoma), KIT/PDGFR mutations (GIST), ALK fusions (IMT), and fusion oncogenes (EWSR1, SS18-SSX) — drive diagnosis and targeted therapy. abinScience provides reagents for MDM2, CDK4, PDGFR, KIT, ALK, Vimentin, Desmin, S100, and CD99. RUO

Key Biomarkers & Targets

MDM2 / CDK4

Well-Differentiated Liposarcoma

MDM2 amplification is pathognomonic for WD/DD liposarcoma; CDK4 co-amplified. MDM2 inhibitors in trials. 10 combined products.

Antibodies • Proteins

KIT / PDGFRα

CD117 / GIST Targets

KIT mutations in ~85% of GIST; PDGFRA mutations in ~5–10%. Imatinib targets. Anti-KIT antibodies with FCM validation. 550+ combined products.

Antibodies • Proteins

ALK

Inflammatory Myofibroblastic Tumor

ALK rearrangements define IMT; crizotinib target. 110+ antibodies and recombinant proteins.

Antibodies • Biosimilars

Vimentin / Desmin

Mesenchymal Markers

Vimentin: pan-mesenchymal marker; Desmin: smooth/skeletal muscle differentiation. Essential IHC markers for sarcoma diagnosis. 80+ combined.

Antibodies • Proteins

CD99

MIC2 / Ewing Sarcoma

Membranous CD99 expression characteristic of Ewing sarcoma/PNET. 12 antibodies and recombinant proteins.

Antibodies • Proteins

S100 / CD34

Neural & Vascular Markers

S100 for MPNST/nerve sheath tumors; CD34 for DFSP and solitary fibrous tumor. 220+ combined antibodies.

Antibodies • Proteins • Biosimilars

Why Researchers Choose abinScience for Sarcoma

Subtype-Specific Diagnostic IHCMDM2/CDK4 (liposarcoma), KIT/DOG1 (GIST), CD99 (Ewing), Desmin/myogenin (RMS), S100 (MPNST) — comprehensive sarcoma classification panel.

GIST Targeted Therapy PanelKIT, PDGFRA, and downstream signaling antibodies for studying imatinib/sunitinib/avapritinib response and resistance in GIST.

Checkpoint ImmunotherapyPD-1, PD-L1, CTLA-4 reagents for characterizing immune microenvironment in sarcoma subtypes with emerging immunotherapy activity (UPS, DDLPS, ASPS).

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

GIST molecular characterization: Use KIT/CD117 and PDGFRA antibodies (IHC, WB) to classify GIST and assess target expression for TKI therapy selection and resistance profiling.
Liposarcoma MDM2/CDK4 profiling: Confirm MDM2 amplification by IHC as a diagnostic marker for WD/DD liposarcoma and assess CDK4 for CDK4/6 inhibitor sensitivity studies.
Ewing sarcoma diagnosis: CD99, NKX2-2, and FLI-1 antibodies available for Ewing sarcoma research. See product pages for validated applications.
Sarcoma differential IHC panel: Vimentin, Desmin, S100, CD34, and related antibodies available for sarcoma subtype classification research. See product pages for validated applications.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

Which KIT antibodies are best for GIST IHC?

Anti-KIT/CD117 monoclonal clone SAA0043 with FC validation. See product pages for full application details.

Do you carry MDM2 antibodies for liposarcoma diagnosis?

Yes. Anti-MDM2 antibodies available. See product pages for validated applications.

What Ewing sarcoma markers do you offer?

We offer anti-CD99 (membranous pattern), plus antibodies for FLI-1 and NKX2-2 as supporting markers. Recombinant EWSR1 protein is available for fusion gene research.

Do you have reagents for rhabdomyosarcoma?

Yes — we carry Desmin, myogenin, MyoD1, and Vimentin antibodies for rhabdomyosarcoma IHC diagnosis and embryonal vs. alveolar subtype differentiation.

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.